Figure 4. Risks for SBM in stage IIIB-IV NSCLC patients without BM at the time of lung cancer diagnosis, characterized by age and EGFR mutation status.

Comparison was conducted using a time-to-event analysis considering death as a competing risk (Fine and Gray's sub-distribution hazard model). P value < 0.05 was considered as significant.